Dr. David Bernstein is chief of the Division of Hepatology / Center for Liver Disease at the North Shore-LIJ Health System , and a professor of medicine at Hofstra North Shore-LIJ School of Medicine . He contributed this article to LiveScience's Expert Voices: Op-Ed & Insights .
Hepatitis C in the News Your source for hepatitis C-related news from around the web.
Not sure what to submit? Read our news guidelines first.
— Separate report calls for more hospice care for terminal cirrhosis patients.
Did you know that Hepatitis C affects an estimated 3.2 million Americans, yet most don't know they're infected? Referred to as a "silent epidemic," Hepatitis C is an infectious liver disease that causes serious health problems including liver damage, cirrhosis, and even liver cancer.
Proper testing is a two-step process in which people who have antibodies get referred for a second more sophisticated test to detect the virus. According to the U.S. Centers for Disease Control and Prevention, many people who have taken a blood test showing they have been infected with the virus…
For the month of May, the Pettis County Health Center, 911 E. 16th Street, will provide free Hepatitis C antibody testing. It is recommended that all "Baby Boomers" (individuals born between 1945 through 1965) be tested. Hepatitis C is a disease of the liver that is caused by the Hepatitis…
A NEW study of 8,976 women attending the Rotunda maternity hospital in Dublin who were tested for hepatitis C found some were infected through tattoos. Of the women who were tested, 78 were positive for the virus and risk factors included drug abuse and tattooing.
— Procedure recommended to treat aggressive liver cancer.
Half of people who have tested positive for hepatitis C don't know if they are still infected, which means many of them aren't getting important medical treatment, the CDC says. (Michael Robinson Chavez / Los Angeles Times) Half of all patients who have tested positive for hepatitis C have not…
— Without treatment, virus can lead to liver cancer.
AMSTERDAM — An investigational protease inhibitor for hepatitis C (HCV) achieved high response rates in treatment-naive patients when given in what one expert called an old-fashioned" regimen.